|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In conclusion, this study shows 1) a reduced expression of NIS gene in most hypofunctioning benign and malignant thyroid tumors; 2) a differential regulation of the expression of thyroid-specific genes; 3) an increased expression of Glut-1 gene in some malignant tumors that may suggest a role for glucose derivative tracers to detect in vivo thyroid cancer metastases by positron emission tomography scanning.
|
10487692 |
1999 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
New strategies, based on manipulation of NIS expression, to obtain NIS gene reactivation or for use as NIS gene therapy in the treatment of radiosensitive cancer, are also being investigated.
|
10576759 |
1999 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, NIS-based gene therapy may have both diagnostic and therapeutic applications for cancer.
|
9973215 |
1999 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Characterization and application of NIS as a novel therapeutic gene and the presence of high native NIS expression in the majority of breast cancers further suggest a promising role of NIS in diagnosis and therapy of cancer outside the thyroid gland.
|
12390328 |
2002 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.
|
12111124 |
2002 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of the sodium iodide symporter (NIS) gene in tumor cells may provide a novel mechanism for treating cancer.
|
12489024 |
2003 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In this review, we discuss the role of the sodium iodide symporter (NIS) as a reporter and therapeutic gene for cancer gene therapy when combined with various radioactive isotopes.
|
14635183 |
2003 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of the NIS gene in tumor cells may provide a novel mechanism for treating cancer.
|
12894520 |
2003 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Transfer of the sodium iodide symporter (hNIS) has been proposed as a new principle of cancer gene therapy.
|
12704416 |
2003 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results demonstrate that NIS expression inhibits MATLyLu cell growth, thereby providing an additional potential benefit of NIS-mediated gene therapy for cancer.
|
12699587 |
2003 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The sodium/iodide symporter (NIS) has been identified as an attractive target for cancer therapy.
|
14602867 |
2003 |
|
Malignant Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter.
|
15522214 |
2004 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NIS gene was transfected into human anaplastic cancer ARO cells using liposome (ARO-N) and its expression was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR).
|
15671766 |
2004 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These findings increase our understanding of the molecular mechanisms that regulate NIS expression in breast cancer cells, information that is fundamental for future research aimed at the development of targeted radioiodide treatment for this type of cancer.
|
15623812 |
2005 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To investigate the pattern of NIS gene expression and provide evidence of its beneficial effects in human anaplastic cancer ARO cells by using a radioactive complementary DNA (cDNA) microarray.
|
16264365 |
2005 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our study indicates that (211)At represents a promising substrate for NIS-mediated therapy of various cancers either with endogenous or gene transfer-mediated NIS expression.
|
16489092 |
2006 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Other types of cancer could also be treated by NIS-mediated concentration of lethal (131)I radiation in tumor cells.
|
16525480 |
2006 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Radioiodide imaging and treatment of ARO cancer xenograft in a mouse model after expression of human sodium iodide symporter.
|
17695547 |
2007 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This study shows that the weak preventive effects of cancer DNA vaccine can be overcome by radioiodine gene therapy utilizing sodium iodide symporter.
|
17565743 |
2007 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Although the success of sodium/iodide symporter (NIS) gene-based cancer therapy is critically dependent on the level of radioiodide accumulation attained, recent evidence indicates that successful therapy relies not solely on NIS amount but also crucially on its functional activity.
|
18997042 |
2008 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To extend the use of NIS-mediated radioiodine therapy to other types of cancer, we successfully transferred and expressed the sodium-iodide symporter (NIS) gene in prostate, colon, and breast cancer cells both in vivo and in vitro by using non-replicating adenoviral vectors.
|
19635153 |
2009 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
|
19861538 |
2009 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We have extended the use of NIS-mediated radioiodine therapy to other types of cancer, we transferred and expressed the NIS gene into prostate, colon and breast cancer cells using adenoviral vectors.
|
20428214 |
2010 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The aim of this study was to investigate the NIS-mediated therapeutic effect of telomerase promoters in a wide variety of human cancer cell lines.
|
21697253 |
2011 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To test the feasibility of using the survivin promoter to induce specific expression of sodium/iodide symporter (NIS) in cancer cell lines and tumors for targeted use of radionuclide therapy, a recombinant adenovirus, Ad-SUR-NIS, that expressed the NIS gene under control of the survivin promoter was constructed.
|
21037556 |
2011 |